載入中
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
NASDAQHealthcareBiotechnology
最新資料
US$10.46
−US$0.02 · -0.19%
收盤時
US$10.46
−US$0.02 · -0.19%
盤後
US$10.46
US$0.00 · 0.00%
10月12日 下午4:12 ET
盤中時間採用ET。市場資料可能有所延遲。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日內區間
目前US$10.46
52週區間
目前US$10.46
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
87
深度低估
情緒
50
多空交錯
風險
38
中等風險
動能
61
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日內區間
目前US$10.46
52週區間
目前US$10.46
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.92億 USD | 2.03億 USD | 1.64億 USD | 1.1億 USD | 4959萬 USD |
| 銷貨成本 | 5341.2萬 USD | 3683.2萬 USD | 2864.5萬 USD | 2263.4萬 USD | 1331.8萬 USD |
| 毛利 | 2.38億 USD | 1.66億 USD | 1.35億 USD | 8761.4萬 USD | 3627.2萬 USD |
| 研究與開發 | 3116.5萬 USD | 2556萬 USD | 2234.1萬 USD | 2096.6萬 USD | 2516萬 USD |
| 銷售、一般及管理費用 | 1.82億 USD | 1.63億 USD | 1.46億 USD | 1.38億 USD | 1.26億 USD |
| 營業費用 | 2.14億 USD | 2億 USD | 1.79億 USD | 1.7億 USD | 1.51億 USD |
| 利息收入 | 474.2萬 USD | 532.1萬 USD | 475.1萬 USD | 257.8萬 USD | 31.3萬 USD |
| 利息支出 | 2908.4萬 USD | 3317.5萬 USD | 2660.9萬 USD | 1410.2萬 USD | 718萬 USD |
| 折舊和攤銷 | 1215.6萬 USD | 1262.5萬 USD | 1316萬 USD | 1266.8萬 USD | 187.9萬 USD |
| 營業利益 | 2489.6萬 USD | −3364.6萬 USD | −4401萬 USD | −8194萬 USD | −1.15億 USD |
| 淨利 | 55.4萬 USD | −5483.6萬 USD | −6225.5萬 USD | −9466萬 USD | −1.23億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$15.00
上漲空間 43.40%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM4668.29萬0.06%787.4億 USD0.19%US$277.88-0.38%
Vanguard Morningstar Total Stock Market ETFVTI4383.45萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF1694.55萬0.02%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1651.43萬0.12%139.17億 USD0.24%US$353.71-0.86%
State Street SPDR S&P Pharmaceuticals ETFXPH1254.51萬2.72%4.62億 USD0.35%US$64.01-0.99%
Fidelity Enhanced Small Cap ETFFESM1163.5萬0.18%64.1億 USD0.28%US$45.24-0.48%
Schwab U.S. Small-Cap ETFSCHA989.65萬0.05%218.24億 USD0.03%US$32.66-0.40%
First Trust Small Cap Growth AlphaDEX FundFYC937.59萬0.69%13.49億 USD0.70%US$114.85-0.44%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMSchwab U.S. Small-Cap ETFSCHAFirst Trust Small Cap Growth AlphaDEX FundFYCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
